Lv11
40 积分 2025-05-16 加入
Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study
1小时前
待确认
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
2小时前
已完结
Non-small-cell lung cancer
20天前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
2个月前
已完结
Clinicopathologic Features of Advanced Squamous NSCLC
2个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
2个月前
已完结
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
3个月前
已完结
Cancer immunotherapy: Pros, cons and beyond
4个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4个月前
已完结
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils
5个月前
已完结
皖公网安备34019202002308
